| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
ML-7 hydrochloride (HCl), a novel naphthalene sulphonamide derivative, is a novel potent inhibitor of Myosin light chain kinase (MLCK) with anticancer effects. It exhibits IC50 of 300 nM and IC50>10 μM for MLCK and TRPC6 channel respectively. Myosin light chain kinase (MLCK) plays a pivotal role in regulation of cellular functions, the evidence often relying on the effects of extracelluarly administered drugs such as ML-9. ML-7 exerts non-specific inhibitory actions on the TRPC6 channel, a transient receptor potential (TRP) protein.
| Targets |
|
|
|---|---|---|
| ln Vitro |
With an IC50 of 0.8 μM, ML-7 hydrochloride inhibits rabbit portal α1-adrenoceptor NSCC[1]. In addition, the myosin light chain kinase (MLCK) inhibitor ML-7 hydrochloride (3 μM, 10 μM) reduced the contraction generated by dexmedetomidine (DMT) (p<0.05 in comparison to the control) [2].
|
|
| ln Vivo |
The ML-7 hydrochloride and vehicle groups did not exhibit different levels of Evans blue extravasation in sham-operated animals (sham+vehicle: 0.26±0.02 OD/g; sham+ML-7 hydrochloride: 0.26±0.02 OD/g). Evans blue levels in the brain were significantly lower in mice treated with CCI than in animals treated with vehicle (CCI+vehicle: 0.42±0.04 OD/g; CCI+ML-7 hydrochloride: 0.35±0.05 OD/g, p =0.048) following MLCK inhibition with ML-7 hydrochloride[3].
|
|
| References |
[1]. Shi J, et al. Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293cells. Br J Pharmacol. 2007 Sep;152(1):122-31.
[2]. Yu J, et al. Dexmedetomidine-Induced Contraction in the Isolated Endothelium-Denuded Rat Aorta Involves PKC-δ-mediated JNK Phosphorylation. Int J Med Sci. 2015 Sep 4;12(9):727-36 [3]. Luh C, et al. Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury. J Neurochem. 2010 Feb;112(4):1015-25. [4]. Pobbati AV, et, al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635 |
| Molecular Formula |
C15H18CLIN2O2S
|
|
|---|---|---|
| Molecular Weight |
452.74
|
|
| CAS # |
110448-33-4
|
|
| Related CAS # |
|
|
| SMILES |
O=S(N1CCNCCC1)(C2=C3C=CC=C(I)C3=CC=C2)=O.[H]Cl
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (3.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2088 mL | 11.0439 mL | 22.0877 mL | |
| 5 mM | 0.4418 mL | 2.2088 mL | 4.4175 mL | |
| 10 mM | 0.2209 mL | 1.1044 mL | 2.2088 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effects of ML-9 and ML-7 on single TRPC6 channels.Br J Pharmacol.2007 Sep;152(1):122-31. |
Activation mode of TRPC6 did not affect the efficacy of ML-9 and ML-7. |
Enhancing actions of ML-compounds on macroscopic TRPC7 current (ITRPC7). Conventional whole-cell recording at −60 mV with Ca2+-free external solution.Br J Pharmacol.2007 Sep;152(1):122-31. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
